Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

This is an open label, single-site, dose-escalation study in up to 18 participants with Relapsed or Refractory Multiple Myeloma, Acute B-Cell Leukemia, and B-Cell Lymphoma. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART

Trial Details

NCT ID
NCT06961669
Phase
NA
Sponsor
Anhui Provincial Hospital
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis
Locations (sample)
  • Hefei, China|31.86389,117.28083

Key Eligibility Criteria

  • The patient or his/her guardian is fully informed and agrees to participate in this clinical study and signs the informed consent form;
  • At the time of signing the informed consent form, be over 3 years of age, regardless of gender;
  • Patients with a confirmed diagnosis of acute B-cell leukemia/B-cell lymphoma/multiple myeloma who meet one of the following criteria:
  • B diffuse large B-cell lymphoma (DLBCL), germinal center, or activated B-cell type; Primary cutaneous DLBCL; Primary mediastinal (thymic) large B-c…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →